Back to Search
Start Over
Intravenous versus subcutaneous immunoglobulin – Authors' reply
- Source :
- Lancet neurology, 17(5), 393-394. Lancet Publishing Group
- Publication Year :
- 2018
- Publisher :
- Lancet Publishing Group; Elsevier, 2018.
-
Abstract
- We thank Ravi Uniyal and colleagues for their comments on our results from the PATH trial1 on subcutaneous immunoglobulin (SCIg) for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (CIDP). They express concern about the relapse rates in the treatment groups and hypothesise the cause being the pharmacokinetics of SCIg.
- Subjects :
- medicine.medical_specialty
biology
business.industry
Medizin
Immunoglobulins, Intravenous
Chronic inflammatory demyelinating polyneuropathy
Subcutaneous immunoglobulin
medicine.disease
Gastroenterology
Pharmacokinetics
Internal medicine
biology.protein
medicine
Administration, Intravenous
Neurology (clinical)
Antibody
business
Subjects
Details
- Language :
- English
- ISSN :
- 14744422
- Database :
- OpenAIRE
- Journal :
- Lancet neurology, 17(5), 393-394. Lancet Publishing Group
- Accession number :
- edsair.doi.dedup.....b5bbab476f42fdc4ef954363ef718221